Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma

Michael A. Thompson; Thomas E. Witzig; Shaji Kumar; Michael M. Timm; Jessica Haug; Rafael Fonseca; Philip R. Greipp; John A. Lust; S. Vincent Rajkumar

doi:10.1046/j.1365-2141.2003.04605.x

Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma

Michael A. Thompson, Thomas E. Witzig, Shaji Kumar, Michael M. Timm, Jessica Haug, Rafael Fonseca, Philip R. Greipp, John A. Lust, S. Vincent Rajkumar

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

We studied marrow angiogenesis and plasma levels of angiogenic cytokines in 38 patients receiving thalidomide therapy for previously untreated myeloma. The effect of therapy and the relationship of cytokine levels to myeloma cell proliferation, bone marrow microvessel density and progression-free survival (PFS) were studied. High pretreatment tumour necrosis factor-α (TNFα) levels (> 11 pg/ml) and increased interleukin (IL)-6 of > 2 pg/ml predicted for poorer PFS (TNFα, 48% versus 74% at 2 years, P = 0. 01; IL-6, 24% versus 70% at 2 years, P = 0.01). None of the other parameters predicted response or PFS, and no significant changes in cytokine levels occurred with therapy.

Original language	English (US)
Pages (from-to)	305-308
Number of pages	4
Journal	British journal of haematology
Volume	123
Issue number	2
DOIs	https://doi.org/10.1046/j.1365-2141.2003.04605.x
State	Published - Oct 2003

Keywords

Angiogenesis
Cytokines
Multiple myeloma
Prognosis
Therapy

ASJC Scopus subject areas

Hematology

Access to Document

10.1046/j.1365-2141.2003.04605.x

Cite this

Thompson, M. A., Witzig, T. E., Kumar, S., Timm, M. M., Haug, J., Fonseca, R., Greipp, P. R., Lust, J. A., & Rajkumar, S. V. (2003). Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. British journal of haematology, 123(2), 305-308. https://doi.org/10.1046/j.1365-2141.2003.04605.x

Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. / Thompson, Michael A.; Witzig, Thomas E.; Kumar, Shaji et al.
In: British journal of haematology, Vol. 123, No. 2, 10.2003, p. 305-308.

Research output: Contribution to journal › Article › peer-review

Thompson, MA, Witzig, TE , Kumar, S, Timm, MM, Haug, J, Fonseca, R, Greipp, PR, Lust, JA & Rajkumar, SV 2003, 'Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma', British journal of haematology, vol. 123, no. 2, pp. 305-308. https://doi.org/10.1046/j.1365-2141.2003.04605.x

@article{61391a6af4294832b880107a5952bf3b,

title = "Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma",

abstract = "We studied marrow angiogenesis and plasma levels of angiogenic cytokines in 38 patients receiving thalidomide therapy for previously untreated myeloma. The effect of therapy and the relationship of cytokine levels to myeloma cell proliferation, bone marrow microvessel density and progression-free survival (PFS) were studied. High pretreatment tumour necrosis factor-α (TNFα) levels (> 11 pg/ml) and increased interleukin (IL)-6 of > 2 pg/ml predicted for poorer PFS (TNFα, 48% versus 74% at 2 years, P = 0. 01; IL-6, 24% versus 70% at 2 years, P = 0.01). None of the other parameters predicted response or PFS, and no significant changes in cytokine levels occurred with therapy.",

keywords = "Angiogenesis, Cytokines, Multiple myeloma, Prognosis, Therapy",

author = "Thompson, {Michael A.} and Witzig, {Thomas E.} and Shaji Kumar and Timm, {Michael M.} and Jessica Haug and Rafael Fonseca and Greipp, {Philip R.} and Lust, {John A.} and Rajkumar, {S. Vincent}",

year = "2003",

month = oct,

doi = "10.1046/j.1365-2141.2003.04605.x",

language = "English (US)",

volume = "123",

pages = "305--308",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma

AU - Thompson, Michael A.

AU - Witzig, Thomas E.

AU - Kumar, Shaji

AU - Timm, Michael M.

AU - Haug, Jessica

AU - Fonseca, Rafael

AU - Greipp, Philip R.

AU - Lust, John A.

AU - Rajkumar, S. Vincent

PY - 2003/10

Y1 - 2003/10

N2 - We studied marrow angiogenesis and plasma levels of angiogenic cytokines in 38 patients receiving thalidomide therapy for previously untreated myeloma. The effect of therapy and the relationship of cytokine levels to myeloma cell proliferation, bone marrow microvessel density and progression-free survival (PFS) were studied. High pretreatment tumour necrosis factor-α (TNFα) levels (> 11 pg/ml) and increased interleukin (IL)-6 of > 2 pg/ml predicted for poorer PFS (TNFα, 48% versus 74% at 2 years, P = 0. 01; IL-6, 24% versus 70% at 2 years, P = 0.01). None of the other parameters predicted response or PFS, and no significant changes in cytokine levels occurred with therapy.

AB - We studied marrow angiogenesis and plasma levels of angiogenic cytokines in 38 patients receiving thalidomide therapy for previously untreated myeloma. The effect of therapy and the relationship of cytokine levels to myeloma cell proliferation, bone marrow microvessel density and progression-free survival (PFS) were studied. High pretreatment tumour necrosis factor-α (TNFα) levels (> 11 pg/ml) and increased interleukin (IL)-6 of > 2 pg/ml predicted for poorer PFS (TNFα, 48% versus 74% at 2 years, P = 0. 01; IL-6, 24% versus 70% at 2 years, P = 0.01). None of the other parameters predicted response or PFS, and no significant changes in cytokine levels occurred with therapy.

KW - Angiogenesis

KW - Cytokines

KW - Multiple myeloma

KW - Prognosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0142246501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142246501&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2003.04605.x

DO - 10.1046/j.1365-2141.2003.04605.x

M3 - Article

C2 - 14531913

AN - SCOPUS:0142246501

SN - 0007-1048

VL - 123

SP - 305

EP - 308

JO - British journal of haematology

JF - British journal of haematology

IS - 2

ER -

Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this